Abigail Brooks, MA

Results showed treatment with iptacopan through 48 weeks caused hemoglobin-level increases, blood transfusion avoidance, and reductions in patient-reported fatigue.

Just 8.5% of eligible patients were screened for hepatitis C - among them, 5.9% tested positive for HCV antibody and 3.0% had an active infection.

Study results presented at the 2023 American Society of Hematology Annual Meeting and Exposition found equal immune tolerance induction success rates regardless of race/ethnicity.

Using data from the 2017-2020 NHANES, investigators found high copper intake and moderate iron intake were associated with a decreased risk of MAFLD.

The seroprevalence of HCV antibody among pregnant women was significantly greater among those with opioid use disorder and HIV infection, as well as in lower-middle-income countries and those with low levels of HDI.

The NDA submission was supported by positive data from the phase 3 PHALCON-NERD-301 study and has been assigned a standard 10-month review with a PDUFA target action date of July 19, 2024.

Results from a systematic review highlighted the clinical need for specific biomarkers for PAD and the viability of noninvasive ophthalmic imaging techniques for diagnosis.

Investigators observed differences in choroidal and inner neural layers among patients previously infected with COVID-19 compared to healthy controls.

The approval was based on data from the APPLY-PNH trial and APPOINT-PNH study, which showed iptacopan was superior for hemoglobin improvement in the absence of red blood cell transfusions and in transfusion avoidance rate compared to patients who stayed on anti-C5 treatments.

The guideline was developed by a multidisciplinary panel and consists of 11 conditional recommendations for the use of biomarkers in the management of Crohn disease.

There was no statistically significant difference in postoperative thromboembolic events and incident heparin-induced thrombocytopenia among patients treated with branded versus biosimilar enoxaparin.

Results showed similar rates of treatment persistence between the groups, with further analysis calling attention to a 40% price reduction in the cost of treatment in Australia due to reference pricing policies between biosimilars and originators.

Investigators ranked ChatGPT responses to healthcare professional-oriented questions about IBD as more useful and reliable than the model’s responses to patient-oriented questions.

Our November 2023 hepatology month in review spotlights data presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases (AASLD) as well as news about hepatitis B and C.

Results showed patients treated with vedolizumab experienced less dose escalation and were at a decreased risk of requiring dose escalation compared to patients treated with adalimumab and infliximab.

November’s Gastroenterology Month in Review features an FDA approval, the discontinuation of a phase 3 clinical program, and news about Clostridioides difficile testing and risk factors.

Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine.

8 weeks of treatment with glecaprevir/pibrentasvir was found to be safe and effective among patients with HCV aged 3-17 years.

Pretreatment vitamin D levels were associated with endoscopic improvement in patients with UC and decreased C-reactive protein levels in patients with CD.

Ciprofloxacin, ceftriaxone, and piperacillin/tazobactam showed the greatest associations with adverse drug reaction case reports related to CDI.

The ultrasound prevalence of NAFLD was 23% among a cohort of patients with IBD, with study results further identifying several clinical characteristics associated with IBD-NAFLD including age, gender, BMI, and waist circumference.

The model uses repeated measurements of longitudinal predictors as opposed to variables collected once at baseline to assess risk of HCC after SVR.

Although respondents agreed on the relevance of the gut microbiota in IBD, attitudes toward the clinical application of microbiome-based therapies varied.

A retrospective cohort study of inpatient encounters from 3 hospitals in the Duke University Health System showed greater rates of testing among White patients compared to Black and NWNB patients.

Results from the 24-week extension period of the phase 2b ENLIVEN trial showed sustained improvements in liver fat, fibrosis, and inflammation among those treated with 30 mg weekly and 44 mg biweekly pegozafermin.

Gideon Hirschfield, PhD, MB BChir, Lily and Terry Horner Chair in Autoimmune Liver Disease Research at the University of Toronto, sat down with HCPLive Hepatology to discuss the role of the microbiome in autoimmune liver disease.

Cynthia Levy, MD, professor of medicine at the University of Miami, provided further insight into unmet needs in PBC, the use of OCA-bezafibrate in PBC, and the significance of results from a pair of phase 2 studies presented at The Liver Meeting.

Results showed significant improvements in serum HDL, CRP, and ESR after treatment with biologic therapies

Receipt of RZV was not associated with an increased risk of incident gout among more than 1,000 adults ≥ 65 years of age who received at least 1 dose of the 2-dose vaccine regimen.

Lifestyle habits including vegetable consumption and exercise were associated with Gout Impact Scale score.